WO2023020423 - ROR1 CAR OR ROR1 /CD19 DUAL CAR T CELLS FOR THE TREATMENT OF TUMORS
National phase entry:
Publication Number
WO/2023/020423
Publication Date
23.02.2023
International Application No.
PCT/CN2022/112449
International Filing Date
15.08.2022
Title **
[English]
ROR1 CAR OR ROR1 /CD19 DUAL CAR T CELLS FOR THE TREATMENT OF TUMORS
[French]
CELLULES CAR T DOUBLE ROR1/CD19 OU CAR ROR1 POUR TRAITER DES TUMEURS
Applicants **
SHANDONG BOAN BIOTECHNOLOGY CO., LTD.
BOAN BOSTON LLC
NANJING BOAN BIOTECHNOLOGY CO. LTD
Inventors
ZONG, Mengqi
JIAO, Jie
FENG, Jianxia
HARRIS, Michael
KAI, Xin
ZHOU, Li
WANG, Ninghai
WEI, Liangjun
CHEN, Hao
WEN, Xian
DOU, Changlin
DONG, Chuangchuang
Priority Data
PCT/CN2021/113420
19.08.2021
CN
202210425699.0
29.04.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2036 | |
| EPO | Filing, Examination, Granting | 12424 | |
| Japan | Filing, Examination, Granting | 2257 | |
| South Korea | Filing, Examination, Granting | 2264 | |
| USA | Filing, Examination, Granting | 8340 |
Total:
27,321
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
An ROR1 CAR or ROR1/CD19 Dual CAR for the treatment of tumors. The T cells expressing ROR1 CAR or ROR1/CD19 Dual CAR can be stimulated by ROR1-positive or ROR1/CD19-positive cells, and have cytotoxicity against ROR1-positive or ROR1/CD19-positive cells.[French]
L'invention concerne un CAR double ROR1/CD19 ou un CAR ROR1 pour traiter des tumeurs. Les cellules T exprimant le CAR ROR1 ou le CAR double ROR1/CD19 peuvent être stimulées par des cellules ROR1-positives ou ROR1/CD19-positives, et ont une cytotoxicité contre les cellules ROR1-positives ou ROR1/CD19-positives.